Efficacy and safety of inhaled iloprost in Japanese patients with pulmonary arterial hypertension - Insights from the IBUKI and AIR Studies

Tsutomu Saji, Masafumi Myoishi, Koichiro Sugimura, Nobuhiro Tahara, Yutaka Takeda, Keiichi Fukuda, Horst Olschewski, Yoshimi Matsuda, Sylvia Nikkho, Toru Satoh

研究成果: Article

12 引用 (Scopus)

抜粋

Background: Inhaled iloprost is approved for pulmonary arterial hypertension (PAH) in many countries. IBUKI was a phase III, non-randomized, open-label study of the efficacy and safety of inhaled iloprost in Japanese patients with PAH. Methods and Results: Adults with PAH who were treatment-naive or administered endothelin receptor antagonists (ERAs) and/or phosphodiesterase type 5 inhibitors (PDE5-Is) and in NYHA/WHO functional class (FC) III/IV had inhaled iloprost (2.5 µug, increased to 5.0 µug if tolerated) 6-9 times daily for 12 weeks. Eligible patients entered a 40-week extension phase. Endpoints included change from baseline to week 12 in pulmonary vascular resistance (PVR; primary endpoint), other efficacy parameters, and safety. Data were compared with new subgroup analyses of treatment-naïve Western PAH patients from the global phase III AIR study. 27 patients received iloprost: 89% were treated with an ERA and/or PDE5-I; 70% with both. At week 12, PVR improved from baseline by -124 dyn sec cm-5 (95% CI, -177 to -72) and 6-min walking distance increased by 36.0 m (95% CI, 14.9 to 57.1). NYHA/WHO FC improved in 62%; none worsened. Common drug-related adverse events were headache (37%) and cough (15%); 1 patient experienced hypotension; none reported syncope or hemoptysis. There were no deaths and no unexpected long-term safety findings. AIR PAH subgroup analyses showed similar results. Conclusions: Inhaled iloprost appeared effective and safe in Japanese PAH patients, including ERA- and PDE5-I-treated patients, consistent with findings of the AIR PAH subpopulation and previous iloprost studies.

元の言語English
ページ(範囲)835-842
ページ数8
ジャーナルCirculation Journal
80
発行部数4
DOI
出版物ステータスPublished - 2016 3 25

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

フィンガープリント Efficacy and safety of inhaled iloprost in Japanese patients with pulmonary arterial hypertension - Insights from the IBUKI and AIR Studies' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Saji, T., Myoishi, M., Sugimura, K., Tahara, N., Takeda, Y., Fukuda, K., Olschewski, H., Matsuda, Y., Nikkho, S., & Satoh, T. (2016). Efficacy and safety of inhaled iloprost in Japanese patients with pulmonary arterial hypertension - Insights from the IBUKI and AIR Studies. Circulation Journal, 80(4), 835-842. https://doi.org/10.1253/circj.CJ-16-0097